Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsTravis, Lois B.
Rabkin, Charles S.
Brown, Linda Morris
Allan, James M.
Alter, Blanche P.
Ambrosone, Christine B.
Begg, Colin B.
Figg, William Douglas
Gospodarowicz, Mary K.
Hall, Eric J.
Little, John B.
Ng, Andrea K.
Robison, Leslie L.
Shields, Peter G.
Tucker, Margaret A.
Greene, Mark H.
MetadataShow full item record
AbstractCancer survivors constitute 3.5% of the United States population, but second primary malignancies among this high-risk group now account for 16% of all cancer incidence. Although few data currently exist regarding the molecular mechanisms for second primary cancers and other late outcomes after cancer treatment, the careful measurement and documentation of potentially carcinogenic treatments (chemotherapy and radiotherapy) provide a unique platform for in vivo research on gene-environment interactions in human carcinogenesis. We review research priorities identified during a National Cancer Institute (NCI)-sponsored workshop entitled "Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers." These priorities include 1) development of a national research infrastructure for studies of cancer survivorship; 2) creation of a coordinated system for biospecimen collection; 3) development of new technology, bioinformatics, and biomarkers; 4) design of new epidemiologic methods; and 5) development of evidence-based clinical practice guidelines. Many of the infrastructure resources and design strategies that would facilitate research in this area also provide a foundation for the study of other important nonneoplastic late effects of treatment and psychosocial concerns among cancer survivors. These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer.
CitationJ. Natl. Cancer Inst. 2006, 98 (1):15-25
DescriptionKEYWORDS - CLASSIFICATION: adverse effects;Antineoplastic Agents;biomarkers of individual susceptibility: validation;Biotechnology;cancer epidemiology;chemically induced;Carcinogens;Case-Control Studies;Clinical Trials;Cohort Studies;Congresses;drug therapy;epidemiology;etiology;genetics;Genetic Predisposition to Disease;Humans;methods;mortality;Medical Informatics;Multicenter Studies;Neoplasms;Neoplasms,Radiation-Induced;Neoplasms,Second Primary;radiotherapy;Radiotherapy;Registries;Research;statistics & numerical data;Specimen Handling;Survivors;Syndrome;United States.
- Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.
- Authors: Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, Cerhan JR, Hartge P, Heist RS, Kushi LH, Lash TL, Morton LM, Onel K, Pierce JP, Robison LL, Rowland JH, Schrag D, Sellers TA, Seminara D, Shu XO, Thomas NE, Ulrich CM, Freedman AN
- Issue date: 2013 Jan 16
- Second malignant neoplasms and cardiovascular disease following radiotherapy.
- Authors: Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD Jr
- Issue date: 2012 Mar 7
- Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.
- Authors: Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK
- Issue date: 2013 May
- The epidemiology of second primary cancers.
- Authors: Travis LB
- Issue date: 2006 Nov
- Second solid cancers after radiotherapy for breast cancer in SEER cancer registries.
- Authors: Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, Ron E
- Issue date: 2010 Jan 5